Myovant Sciences Operating Margin 2017-2022 | MYOV
Current and historical operating margin for Myovant Sciences (MYOV) over the last 10 years. The current operating profit margin for Myovant Sciences as of March 31, 2022 is -89.18%.
|Myovant Sciences Operating Margin Historical Data
||TTM Operating Income
||Medical - Biomedical and Genetics
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.